MRPL12 and neoplasm: YTHDC2 also targeted m6A-modified mitochondrial ribosomal protein L12 (MRPL12) mRNA, inhibiting LUAD tumor growth and metastasis, while promoting apoptosis, and ultimately suppressing tumor occurrence [42].